Chimeric Therapeutics (ASX:CHM) September Quarter: Progress in Cancer Trials and Strategic Partnerships

November 12, 2024 11:01 AM AEDT | By Aditi Saha

Google News:

Chimeric Therapeutics (ASX:CHM) September Quarter: Progress in Cancer Trials and Strategic Partnerships — Image source: Company update

Recent News

Achieving Safety Excellence: Covia’s TRIR Progress and Initiatives

Connected by Pipeline: Marathon and Osage Nation Find Success

Logitech Celebrates #Creators4BIPOC With New Community Initiatives, Cr...

Technical Resonance, Ecological Win-Win: Baijiayun and Kingsoft Office...

Highlights

Chimeric Therapeutics dosed the first patient in its Phase 1/2 clinical trial for CHM CDH17 CAR-T cell therapy.

In September, Chimeric announced collaboration with Achieve Clinics to expand access to CHM CDH17 through Achieve’s PRO-Aph™ process.

The company formed a partnership with Cell Therapies Pty Ltd to explore the manufacturing of its CAR T-cell therapies in Australia.

Chimeric’s CHM CORE-NK Phase 1b combination trial reported a complete response in an acute myeloid leukemia patient.

Chimeric Therapeutics Limited (ASX:CHM) achieved significant milestones in the September 2024 quarter, including the enrollment and dosing of the first patient in the CHM CDH17 Phase 1/2 trial. This trial aims to guide dose selection, with plans for Phase 2 expansion targeting specific cancer cohorts.

Chimeric also expanded the patient access to CHM CDH17 through a partnership with Achieve Clinics and teamed up with Cell Therapies Pty Ltd to explore CAR T cell manufacturing in Australia.

Phase 1/2 Trial for CHM CDH17 CAR-T Advances

In August, Chimeric Therapeutics dosed the first patient in its Phase 1/2 clinical trial for CHM CDH17 CAR-T cell therapy at the Sarah Cannon Research Institute in Nashville, Tennessee. This trial is enrolling patients with advanced colorectal cancer, gastric cancer, and intestinal neuroendocrine tumours at multiple US cancer centres.

The University of Pennsylvania (Penn) also began enrolling patients for the trial, with additional sites anticipated to open by the end of 2024.

In September, the company announced a collaboration with Achieve Clinics to expand access to CHM CDH17 through Achieve’s PRO-Aph™ process, which is expected to improve cell collection early in the cancer treatment process and enhance patient recruitment and trial timelines.

Chimeric Partners with Cell Therapies

Chimeric Therapeutics has announced a strategic partnership with Cell Therapies Pty Ltd to explore the manufacturing of its CAR T-cell therapies in Australia. This collaboration aims to provide Australian patients with access to Chimeric’s cutting-edge clinical trials, focused on cancer treatment through CAR T and NK cell therapies. With four clinical trials currently underway in the US, Chimeric is also considering the addition of Australian sites to broaden patient access.

Post-quarter, Chimeric reported a notable achievement in its CHM CORE-NK Phase 1b combination trial: an Acute Myeloid Leukemia (AML) patient achieved a complete response. Additionally, the company secured commitments for a AU$5 million capital raise.

Chimeric also received AU$1.56 million from Endpoints Capital, under a facility linked to the company’s anticipated FY24 Research and Development Tax Incentive (RDTI). The funds will support the clinical trial pipeline.

The share price of CHM was AU$0.010 as on 11 November 2024.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.